On the basis of the results of this trial, combination nivolumab and ipilimumab is now a Food and Drug Administration–approved regimen for EGFR/ALK alteration-negative NSCLC with PD-L1 greater than or equal to 1% in the United States. Here, CD274 is linked to non-small cell lung carcinoma.